GALT

Galectin Therapeutics

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$32.6M

Burn Rate (Qtr)

$5.9M

Company Profile

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Belapectin (GR-MD-02)

NASH-cirrhosis

Phase 3

TBD

Belapectin (GR-MD-02)

Plaque Psoriasis

Phase 2

TBD

Belapectin (GR-MD-02)

NASH-Fibrosis

Phase 2

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon